Skip to main content
Arcus Biosciences, Inc. logo

Arcus Biosciences, Inc. — Investor Relations & Filings

Ticker · RCUS ISIN · US03969F1093 US Manufacturing
Open in API
Filings indexed 549 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country US United States of America
Listing US RCUS

About Arcus Biosciences, Inc.

https://arcusbio.com/

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer. The company's approach centers on creating both small molecules and antibodies designed to be combined for greater efficacy. Its pipeline of investigational medicines is guided by specific biologic mechanisms of cancer, with a strategy aimed at accelerating the development of novel combination treatments from early-stage clinical studies through to potential commercialization. Arcus Biosciences collaborates with the broader cancer community to advance its global clinical trials.

Recent filings

Filing Released Lang Actions
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes the discontinuation of a clinical trial (STAR-121) and updates on a collaboration agreement with Gilead Sciences. There are no financial statements or detailed financial performance data presented. The document is an event announcement rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-20 English
8-K - Arcus Biosciences, Inc. (0001724521) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the resignation of a Chief Operating Officer and related separation agreement details. This corresponds to an announcement of changes in senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and contains substantive information about management changes, not just a notice or link to a report, so it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2026-03-23 English
S-3ASR - ARCUS BIOSCIENCES, INC. (0001724521) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 registration statement filed with the SEC, which is used by companies to register securities for sale to the public. It includes a base prospectus and an equity distribution agreement prospectus, describing the offering, issuance, and sale of common stock, preferred stock, debt securities, and warrants. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a registration statement rather than a brief announcement or report publication notice.
2026-02-25 English
10-K - ARCUS BIOSCIENCES, INC. (0001724521) (Filer)
Annual Report FY 2025
2026-02-25 English
8-K - ARCUS BIOSCIENCES, INC. (0001724521) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 25, 2026, by Arcus Biosciences, Inc. It announces the issuance of a press release with financial results for the quarter and full year ended December 31, 2025. The text explicitly states that the press release is furnished as an exhibit and incorporated by reference, and the document itself is a current report rather than the full financial report. The document length is 3839 characters, which is relatively short and consistent with an announcement rather than a full earnings release. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to an Earnings Release announcement in an 8-K. Therefore, this document is best classified as an Earnings Release (ER) announcement rather than a full Annual Report or Interim Report. Confidence is high given the clear SEC form type and content.
2026-02-25 English
4 Filing
Director's Dealing
2026-01-26 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.